摘要
目的研究吉非替尼靶向治疗对肺腺癌患者生活质量的影响。方法选取2009年1月-2011年6月就诊于我院接受吉非替尼靶向治疗的晚期肺腺癌患者32例,治疗方案为口服吉非替尼,一日1次、每次250 mg。通过FACT-L量表评价患者治疗前、治疗1周、治疗1个月、治疗3个月及疾病进展(PD)五个时间点的生活质量。结果至随访结束时,患者均出现PD。中位PFS时间为7.03个月。治疗3个月和PD两个时间点FACT-L总分与其他各时间点总分差异显著。分领域得分分析表明,不同时间点的FWB和LCS差异有统计学意义。结论吉非替尼靶向治疗晚期肺腺癌可改善患者治疗期间的生活质量。
Objective To observe the influence of gefitinib targeted therapy on advanced lung adenocarcinomas patient＇s life quality. Methods Thirty-two cases of advanced lung adenocarcinoma patients were collected and given gefitinib 250 mg once daily. Quality of life was evaluated by FACT-L investigation before treatment and after treatment for the 1^st week, the 1^st month, the 3^rd month and the disease progression （PD）. Results All patients occurred PD at the cutoff date. The median PFS was 7.03 months. Compared with other time points, the total scores at the 3^rd month after treatment and time of PD had significant differences. The FWB and LCS scores in different time points had significant differences. Conclusion Gefitinib can improve advanced lung adenocarcinomas patient＇s life quality during treatment process.
出处
《世界临床药物》
CAS
2015年第11期767-770,共4页
World Clinical Drug
基金
国家自然科学基金面上项目(编号:81472175)
上海市卫生和计划生育委员会重点项目(编号:20134007)
关键词
吉非替尼
靶向治疗
晚期肺腺癌
生活质量
gefitinib
targeted therapy
advanced lung adenocarcinomas
quality of life
